Skip to content

Evaluation of the efficacy and safety of Guhong injection in the treatment of ischemic stroke Multicenter, randomized controlled clinical trial

Evaluation of the efficacy and safety of Guhong injection in the treatment of ischemic stroke Multicenter, randomized controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078431
Enrollment
Unknown
Registered
2023-12-08
Start date
2023-12-10
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Experimental group:On the basis of basic treatment (reducing intracranial pressure, anti platelet aggregation, controlling blood lipids and blood sugar, correcting water electrolyte disorders, nutriti
control group:On the basis of basic treatment (reducing intracranial pressure, anti platelet aggregation, controlling blood lipids and blood sugar, correcting electrolyte imbalances, nutritional suppo

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age range from 35 to 80 years old, regardless of gender; 2. <48 hours from onset to treatment; The time when symptoms begin is defined as the 'last time they appear normal'; 3. Clinical diagnosis of ischemic stroke (diagnosis follows the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018"); 4. MRS = 1 point before onset, baseline 4 = NIHSS = 24 points; 5. The subject or their trustee agrees and voluntarily signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Age range from 35 to 80 years old, regardless of gender; 2. ULN; Those who have been assessed by researchers as unable to cooperate in completing clinical trials in terms of their psychological, mental or cognitive abilities, language expression abilities, etc; 5. After active antihypertensive treatment, hypertension remains uncontrolled: systolic blood pressure = 220mmHg, or diastolic blood pressure = 120mmHg, with acute bleeding tendencies, including platelet counts below 75.0 × 10 ^ 9/L or other circumstances; Blood glucose22.22mmol/L; 6. Pregnant women, lactating women, or subjects who do not agree to effective contraceptive measures during the trial period; Suspected or with a history of alcohol or drug abuse; 7. Participate in other clinical trials within 3 months prior to screening; 8. According to the judgment of the researcher, it is not suitable to participate in this study or participating in this study may result in greater risk for the subjects.

Design outcomes

Primary

MeasureTime frame
MRS score;

Secondary

MeasureTime frame
NIHSS score;

Countries

China

Contacts

Public ContactWang Chaoxia

Peking University First Hospital

wangchaoxia@126.com+86 10 8357 2544

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026